Operations Lead, Sable Bio
£40-60k
Comprehensive target safety intelligence in one place
Job no longer available
Comprehensive target safety intelligence in one place
1-20 employees
Job no longer available
£40-60k
1-20 employees
Company mission
Navigate target safety with augmented intelligence.
Role
Who you are
- 2+ years of experience in operations management, program management, business operations, or similar roles - ideally in a fast-growing tech or biotech company
- Track record of implementing and improving company processes
- Strong stakeholder management experience
- Ability to work in an agile and flexible environment where processes may be unclear or need to be developed
- Experience with operational/project management software and systems
- Outstanding communication and interpersonal skills
Desirable
- Experience in biotech or healthcare industries
- Experience with vendor contracts renewals, vendor oversight, license renewals, CDA
- Experience managing external partnerships or investor relations
- Track record of implementing process improvements in a startup environment
- Background in agile project management methodologies
- A collection of questionable science puns
What the job involves
- Oversee and optimize core business operations, from office management to external relationships
- Manage company benefits and HR programs
- Locating gaps in processes, developing processes and process improvements for the company
- Lead operational budgeting and resource allocation
- Support team growth through improved onboarding and administrative processes
- Support strategic planning and company growth initiatives
- This role will report directly to one of the co-founders
Application process
- 1. Video call with hiring manager (30 minutes)
- 2. Video call presentation + Q&A with hiring manager + 2 attendees (45 minutes)
- 3. Onsite team meet, soft skills, and final technical questions (2 hours)
Salary benchmarks
Our take
Sable Bio is stepping into an essential area of biotechnology, where drug safety is a top priority. As demand for new, safer medicines rises, toxicity-related issues often slow down drug development, causing costly delays or failures. With AI and data-driven solutions gaining traction, there's a real opportunity to make safety assessments faster and more efficient.
What makes Sable unique is its use of AI to improve drug safety assessments. With this, Sable analyzes various biomedical data sets to detect potential toxicity in new medicines before human trials. By tapping into the scientific literature and diverse data sources, it spots safety risks quicker, helping drug developers make better decisions and save them time and money.
The company has secured substantial funding, which will help it expand its technology and form key partnerships with biotech, pharma, and healthtech companies. As Sable continues to grow, its platform has the potential to transform drug development by reducing risks and improving patient outcomes.
Kirsty
Company Specialist at Welcome to the Jungle
Company
Funding (1 round)
Jan 2024
$2.1m
Early VC
Total funding: $2.1m
Company benefits
- Every Friday afternoon free for personal development
- Private medical plan
- Annual training budget for professional development
- Opportunity to shape the future of our company and grow as we grow
Company HQ
Spitalfields, London, UK
Leadership
Alex de Giorgio
(Co-Founder & CEO)Prior to founding Sable, Alex worked at BenevolentAI, leading multiple disease deployments, and pioneering new methods for relationship extraction.
Josh Almond-Thynne
(Co-Founder & CSO)Prior to founding Sable, Josh helped deliver two pre-clinical candidates as a medicinal chemist at BenevolentAI. He pioneered the use of unstructured data in medicinal chemistry.
Olly Oechsle
(CTO)Prior to joining Sable, Olly spent eight years at BenevolentAI working on applications, data pipelines and Natural Language Processing (NLP) techniques, as VP of Product Engineering.
Share this job